Prosight Management’s ProQR Therapeutics PRQR Stock Holding History

Prosight Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,716,290	Closed	-$1.28M	–	49
2022 Q3	$1.28M	Buy	1,716,290 +8,781	+0.5%	+$7.05K	0.68%	31
2022 Q2	$1.33M	Buy	1,707,509 +1,108,221	+185%	+$826K	1.05%	20
2022 Q1	$542K	Buy	599,288 +242,671	+68%	+$813K	0.35%	29
2021 Q4	$2.86M	Buy	356,617 +74,361	+26%	+$566K	1.71%	18
2021 Q3	$2.36M	Sell	282,256 -137,744	-33%	-$900K	1.3%	29
2021 Q2	$2.83M	Sell	420,000 -30,165	-7%	-$195K	1.77%	21
2021 Q1	$2.98M	Buy	450,165 +195,165	+77%	+$997K	2.44%	15
2020 Q4	$1.07M	Buy	+255,000	New	+$1.08M	0.49%	34

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management's PRQR Position: Q4 2022 in Review

Prosight Management sold out of ProQR Therapeutics (PRQR) in Q4 2022, closing a stake of 1,716,290 shares — an estimated $1.28M sold.

Prosight Management first reported a position in PRQR in Q4 2020 and held it in 8 quarters. The position peaked at $2.98M in Q1 2021. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2022.

Prosight Management reported no remaining ProQR Therapeutics position as of Q4 2022 after selling out during the quarter.
Prosight Management sold 1,716,290 ProQR Therapeutics shares in Q4 2022, an estimated $1.28M.
Prosight Management first reported a position in ProQR Therapeutics in Q4 2020 and held it in 8 quarters.
Prosight Management's ProQR Therapeutics position peaked at $2.98M in Q1 2021.
46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2022.

Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.